Rabies Virus Vaccine

Table of contents

  • Brand Names
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Rabipur; Bulgaria: Rabipur, Verorab; Czech Republic: Rabipur, Verorab; Denmark: Rabies Imovax; Estonia: Verorab; Finland: Rabies-Imovax; France: Rabipur; Germany: Enduracell T, Guardvax Rabies, Rabdomun, Rabipur, Rabivac, Tollwut-Impfstoff (HDC) Inaktiviert; Ireland: Rabies Vaccine, Rabipur; Latvia: Verorab; Lithuania: Verorab; Luxembourg: Vaccin Rabique; Netherlands: Rabiesvaccin; Poland: Rabipur, Verorab; Portugal: Rabipur; Romania: Rabipur, Verorab; Slovakia: Imovax Rabies, Rabipur, Verorab; Spain: Rabipur, Vacuna Antirrábica Merieux; Sweden: Rabies-Imovax, Rabipur; UK: Rabies Vaccine, Rabipur.

North America

Canada: Imovax Rabies, RabAvert; USA: Imovax Rabies, RabAvert.

Latin America

Argentina: Verorab; Brazil: Vacina Anti-rábica Humana Prep Cel Vero.


Japan: Freeze-dried inactivated tissue culture rabies vaccine.

Drug combinations


Pharmacologic Category

Serums, Toxoids, and Vaccines; Vaccines. (ATC-Code: J07BG).

Mechanism of action

Inactivated virus vaccine which promotes immunity by inducing active immune response. Rabies immune globulin or antirabies serum, equine, is administered in conjunction with rabies vaccine to provide immune protection until antibody response can occur.

Therapeutic use

Pre-exposure immunization, and postexposure prophylaxis. Rabies.

Pregnancy and lactiation implications

Use with caution during pregnancy and breast-feeding.

Unlabeled use


Hypersensitivity to any component of the formulation. Developing febrile illness. Life-threatening allergic reactions to rabies vaccine or any components of the formulation.

Warnings and precautions

Anaphylactic/anaphylactoid reactions might occur. An immune complex reaction characterized by generalized urticaria, arthralgia, arthritis, angioedema, nausea, vomiting, fever, and malaise reported 2-21 days following booster doses of human diploid cell vaccine. Immune response may be decreased in immunocompromised patients. Pre-exposure immunization does not eliminate need for prompt prophylaxis following exposure but does reduce postexposure treatment regimen. Administer with caution in thrombocytopenia or any coagulation disorder which would be compromised by I.M. injection.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart